Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2008
Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells.
Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.The Cochrane database of systematic reviews · 2017Pooled it
- Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study.Annals of transplantation · 2018Trial
- Regulatory T cells in cardiac allograft vasculopathy: from mechanistic insights to clinical tolerance.Frontiers in immunology · 2026Review
- Age-related effects on thymic output and homeostatic T cell expansion following depletional induction in renal transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Cyclosporine A but Not Corticosteroids Support Efficacy ofFrontiers in immunology · 2021Article
- Cell Therapy in Kidney Transplantation: Focus on Regulatory T Cells.Journal of the American Society of Nephrology : JASN · 2017Review
- mTOR inhibitors effects on regulatory T cells and on dendritic cells.Journal of translational medicine · 2016Review
- Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.Drugs · 2015Review
- Regulatory T-cell therapy in transplantation: moving to the clinic.Cold Spring Harbor perspectives in medicine · 2013Review
- Ex vivo-expanded cynomolgus macaque regulatory T cells are resistant to alemtuzumab-mediated cytotoxicity.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013Article
- BIOMARKERS OF OPERATIONAL TOLERANCE IN SOLID ORGAN TRANSPLANTATION.Expert opinion on medical diagnostics · 2012Article
- B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2012Article
- The role of B cells in solid organ transplantation.Seminars in immunology · 2012Review
- CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.Journal of molecular cell biology · 2012Review
- Favorable effects of alemtuzumab on allospecific regulatory T-cell generation.Human immunology · 2012Article
- Delayed graft function in the kidney transplant.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2011Review
- Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?Paediatric drugs · 2011Review
- Review
- Overview of immunosuppression in liver transplantation.World journal of gastroenterology · 2009Review
- BAFF is increased in renal transplant patients following treatment with alemtuzumab.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
To address the results of calcineurin inhibitor (CNI) withdrawal after alemtuzumab induction relative to CNI continuation, we performed a pilot randomized clinical trial in renal allograft recipients on CNI, a mycophenolic acid derivative and steroids after the first 2 months posttransplantation. Forty patients were randomized to taper off CNI or to maintain it, and followed for at least 1 year. Four patients in the withdrawal group were treated for acute rejection while no patient received antirejection treatment in the control group. Two control patients withdrew CNI due to nephrotoxicity. Estimated GFR was similar in both groups after 1 year. Flow cytometry of CD4(+)CD25(+)CTLA-4(+)FoxP3(+) regulatory T cells (Treg) demonstrated a significant increase in Treg percentages in the peripheral blood of alemtuzumab-treated patients on CNI early postransplant. Furthermore, the increased Treg percentages in the withdrawal cohort were unchanged at month 6 postenrollment, whereas they decreased significantly in those patients maintained on CNI. Patients withdrawn from CNI after alemtuzumab trend toward a higher rejection rate, but most patients can be weaned from a CNI using this regimen. With the exception of maintaining increased Treg levels, the benefits are not appreciable in this short follow-up, and a larger randomized trial is justified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.